Inflammation is a key feature of the self-perpetuating vicious circle in the evaporative and aqueous forms of dry eye disease. Therapeutics aim to break this cycle and reinstate tear film and ocular surface homeostasis. But given today’s vast range of available and developing therapeutic options, ad
The BCLA virtual conference was a breath of fresh air. Organisers took a arranged four back-to-back sessions over a 30-hour period, giving members from across the world the benefit of 'live' sessions.
Meibomian gland dysfunction (MGD) is characterised by alterations in glandular secretion and terminal duct obstruction, secondary to hyperkeratinisation of the ductal epithelium1. The oils secreted from the glands contain a mixture of lipid secretions and keratinised epithelial debris. Keratin level
Placement - Dry eye special feature, dry eye-focused news brief to fill any gaps from middle to end – say p36-49 – please use this one
A report by The Business Research Company predicts that the global dry eye medication market will grow to around US$4.8bn in 2025, up from US$2.9bn in 2015.
According to the large Dry Eye Assessment and Management (DREAM) study, patients with facial rosacea and peripheral artery disease experience more severe dry eye disease symptoms.
Dry eye disease (DED) is one of the most common yet undertreated ocular surface conditions. The Tear Film and Ocular Surface Society’s second Dry Eye Workshop (TFOS DEWS II) recognised DED as a multifactorial, self-perpetuating vicious circle characterised by tear film instability and hyperosmolarit
The mainstay therapy for dry eye disease (DED) is the use of artificial tear solutions to supplement the natural tear film1. The therapeutic landscape has recently seen a considerable evolution of
Self-reported symptoms of mask-associated dry eye
Allegro Ophthalmics, a privately held US biopharmaceutical company, has announced that all primary and secondary endpoints of a 64-eye vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met.
Titan Optical is the new New Zealand agent for Quantel Medical, distributing Quantel’s full suite of retinal lasers, ultrasound products and dry eye product ranges.
Significant gaps exist in public awareness of dry eye disease (DED), its symptoms and treatments, including among people who have experienced symptoms themselves, a UK survey has found.
